StemCells Inc.

www.stemcellsinc.com

USA

7707 Gateway Blvd., Suite 140 Newark, CA 94560

NASDAQ:STEM

StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics. The Company is focused on developing and commercializing stem and progenitor cells as the basis for therapeutics and therapies. The Company's lead product development program is its CNS Program, in which it is developing applications for HuCNS-SC cells, its human neural platform technology. It is in clinical development with its HuCNS-SC cells for a range of diseases and disorders of the central nervous system. The CNS consists of the brain, spinal cord and eye, and it is stem cell company in clinical development for indications in all three compartments comprising the CNS, which include with respect to the brain, with respect to the spinal cord and with respect to the eye. The Phase I clinical trial was completed in Pelizeaus-Merzbacher Disease, Neuronal Ceroid Lipofuscinosis and Phase I/II clinical trial in multiple sites for chronic spinal cord injury was completed.